nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.07.2012 | Preclinical Study

Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer

verfasst von: Alaa T. Alshareeda, Emad A. Rakha, Christopher C. Nolan, Ian O. Ellis, Andrew R. Green

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

FABP7 is a member of the multi-gene fatty acid binding protein family. It is expressed in the mammary gland and has been shown to function as inhibitor of proliferation of breast tumour cells and to promote differentiation through the JAK/Stat pathway. Cytoplasmic FABP7 expression has been shown to be associated with a favourable prognosis of basal-like breast cancer. In other tissues, varying sub-cellular localization of FABP7 between the nucleus and cytoplasm has been observed. Tissue microarray preparations of well-characterized series of 1,249 unselected and 245 ER-negative invasive breast cancers with a long-term follow-up were investigated in this study to assess the biological and clinical significance of FABP7 sub-cellular localization using immunohistochemistry. Both nuclear and cytoplasmic FABP7 were observed. Nuclear FABP7 was associated with high histologic grade, mitotic frequency, pleomorphism and stage, in addition to basal phenotype (BP) and triple-negative (TN) phenotype. Nuclear FABP7 expression showed an association with expression of markers associated with proliferation and cell-cycle control including Ki67, p53 and p21; however, cytoplasmic FABP7 was associated only with Ki67 and P53 (P = 0.001, < 0.001 respectively). Interestingly, in multivariate analysis, nuclear FABP7 expression in BP was significantly associated with longer DFI (P = 0.025) independent of cytoplasmic expression. Tumours with only nuclear positive FABP7 expression had significantly better prognosis than those with only cytoplasmic expression. This is the first study elucidating the sub-cellular localization of FABP7 in a large series of breast cancer cases. Our observations demonstrate the considerable heterogeneity in expression patterns of FABP7 within breast cancer that relates to differences in biological behaviour especially in basal-like breast cancer. Further investigation of the biology of FABP7 in breast cancer is warranted.

Xu LZ, Sánchez R, Sali A, Heintz N (1996) Ligand specificity of brain lipid-binding protein. J Biol Chem 271(40):24711–24719PubMedCrossRef

Wolfrum C, Borrmann CM, Borchers T, Spener F (2001) Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha—and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA 98(5):2323–2328. doi:10.1073/pnas.051619898051619898 PubMedCrossRef

Huang H, Starodub O, McIntosh A, Kier AB, Schroeder F (2002) Liver fatty acid-binding protein targets fatty acids to the nucleus. J Biol Chem 277(32):29139PubMedCrossRef

Feng L, Heintz N (1995) Differentiating neurons activate transcription of the brain lipid-binding protein gene in radial glia through a novel regulatory element. Development 121(6):1719–1730PubMed

Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara T (1997) Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). Biochim Biophys Acta 1354(1):24–28. doi:S0167-4781(97)00115-2 PubMedCrossRef

Godbout R, Bisgrove DA, Shkolny D, Day RS 3rd (1998) Correlation of B-FABP and GFAP expression in malignant glioma. Oncogene 16(15):1955–1962. doi:10.1038/sj.onc.1201740 PubMedCrossRef

Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, Delattre JY, Godbout R, Sanson M (2007) FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol 84(3):245–248PubMedCrossRef

Mita R, Beaulieu MJ, Field C, Godbout R (2010) Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J Biol Chem 285(47):37005–37015. doi:10.1074/jbc.M110.170076 PubMedCrossRef

Haunerland NH, Spener F (2004) Fatty acid-binding proteins–insights from genetic manipulations. Prog Lipid Res 43(4):328–349. doi:10.1016/j.plipres.2004.05.001S016378270400013X PubMedCrossRef

10.

Wang M, Liu YE, Ni J, Aygun B, Goldberg ID, Shi YE (2000) Induction of mammary differentiation by mammary-derived growth inhibitor-related gene that interacts with an omega-3 fatty acid on growth inhibition of breast cancer cells. Cancer Res 60(22):6482–6487PubMed

11.

Shi YE, Ni J, Xiao G, Liu YE, Fuchs A, Yu G, Su J, Cosgrove JM, Xing L, Zhang M (1997) Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res 57(15):3084PubMed

12.

Tölle A, Krause H, Miller K, Jung K, Stephan C (2011) Importance of brain–type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. Oncol Rep 25(5):1307–1312PubMedCrossRef

13.

Takaoka N, Takayama T, Teratani T, Sugiyama T, Mugiya S, Ozono S (2011) Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines. BMC Mol Biol 12:31. doi:10.1186/1471-2199-12-31 PubMedCrossRef

14.

Glatz JFC, Luiken JJFP, van Bilsen M, van der Vusse GJ (2002) Cellular lipid binding proteins as facilitators and regulators of lipid metabolism. Mol Cell Biochem 239(1):3–7PubMedCrossRef

15.

Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7(3):403–417PubMedCrossRef

16.

Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, Powe DG, Macmillan RD, Caldas C, Ellis IO, Green AR (2010) The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 121(1):41–51. doi:10.1007/s10549-009-0450-x PubMedCrossRef

17.

Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200(5):633–639. doi:10.1002/path.1357 PubMedCrossRef

18.

Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568–2581PubMedCrossRef

19.

García-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:472–480PubMedCrossRef

20.

Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal KR, Reis-Filho JS, Ellis IO, Rakha EA (2011) Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer. Breast Cancer Res 14(1):R3CrossRef

21.

Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E (2001) Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 70(3):255–264PubMedCrossRef

22.

Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PDP, Caldas C (2003) Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12(1):27PubMedCrossRef

23.

Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adélaïde J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, Houlgatte R, Birnbaum D, Jacquemier J (2002) Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161(4):1223–1233PubMedCrossRef

24.

Feng L, Hatten ME, Heintz N (1994) Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. Neuron 12(4):895–908PubMedCrossRef

25.

Liang Y, Bollen AW, Aldape KD, Gupta N (2006) Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 6:97. doi:10.1186/1471-2407-6-97 PubMedCrossRef

26.

Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, Nguyen L, Nguyen T, Ye X, Morton DL (2009) Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J Invest Dermatol 130(1):221–229CrossRef

27.

Yang Y, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW, Pizer ES (2003) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282(2):132–137PubMedCrossRef

28.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.19136709898/19/10869 PubMedCrossRef

29.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492 PubMedCrossRef

30.

Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D, Ellis IO (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156. doi:10.1016/j.ejca.2006.08.015 PubMedCrossRef

31.

Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9(1):R4. doi:10.1186/bcr1636 PubMedCrossRef

32.

Tang XY, Umemura S, Tsukamoto H, Kumaki N, Tokuda Y, Osamura RY (2010) Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer. Pathol Res Pract 206(2):98–101. doi:10.1016/j.prp.2009.06.010 PubMedCrossRef

33.

Aksglaede L, Wikstrom AM, Rajpert-De Meyts E, Dunkel L, Skakkebaek NE, Juul A (2006) Natural history of seminiferous tubule degeneration in Klinefelter syndrome. Hum Reprod Update 12(1):39–48. doi:10.1093/humupd/dmi039 PubMedCrossRef

34.

Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, Walter MA, Martens JW, Richardson AL, Giuliano AE, Cui X (2010) FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 70(10):3870–3876. doi:10.1158/0008-5472.CAN-09-4120 PubMedCrossRef

35.

Liang Y, Bollen AW, Nicholas MK, Gupta N (2005) Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas. BMC Clin Pathol 5:6. doi:10.1186/1472-6890-5-6 PubMedCrossRef

36.

Solomayer EF, Diel I, Meyberg G, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271–278PubMedCrossRef

37.

Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602PubMedCrossRef

38.

Niwińska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21(5):942–948PubMedCrossRef

39.

Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. The American journal of surgical pathology 30(9):1097PubMedCrossRef

40.

Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A (2009) Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 276(2):212–220PubMedCrossRef

41.

Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, Murata H, Takata M, Aburatani H, Hoon DSB (2006) A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 66(8):4443PubMedCrossRef

42.

Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4(1):61–70. doi:10.1038/nrc1254nrc1254 PubMedCrossRef

43.

Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K (1998) Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 95(18):10626–10631PubMedCrossRef

44.

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008) The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer 8(1):276PubMedCrossRef

Titel: Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer
verfasst von: Alaa T. Alshareeda
Emad A. Rakha
Christopher C. Nolan
Ian O. Ellis
Andrew R. Green
Publikationsdatum: 01.07.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2083-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy

Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease

Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients

High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?

Long-term survival of older breast cancer patients: population-based estimates over three decades

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie